HRP20050886B1 - Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol - Google Patents

Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol

Info

Publication number
HRP20050886B1
HRP20050886B1 HR20050886A HRP20050886A HRP20050886B1 HR P20050886 B1 HRP20050886 B1 HR P20050886B1 HR 20050886 A HR20050886 A HR 20050886A HR P20050886 A HRP20050886 A HR P20050886A HR P20050886 B1 HRP20050886 B1 HR P20050886B1
Authority
HR
Croatia
Prior art keywords
alkyl
alkoxycarbonyl
branched
straight
carbon chain
Prior art date
Application number
HR20050886A
Other languages
English (en)
Croatian (hr)
Inventor
Oomura Tomoyuki
Pudipeddi Madhusudhan
Edward Royce Alan
Ruegger Colleen
Sasaki Masaki
Tamura Tokuhiro
Original Assignee
Novartis Ag
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050886(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corporation filed Critical Novartis Ag
Publication of HRP20050886A2 publication Critical patent/HRP20050886A2/xx
Publication of HRP20050886B1 publication Critical patent/HRP20050886B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HR20050886A 2003-04-08 2004-04-06 Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol HRP20050886B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Publications (2)

Publication Number Publication Date
HRP20050886A2 HRP20050886A2 (en) 2006-11-30
HRP20050886B1 true HRP20050886B1 (en) 2011-01-31

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20050886A HRP20050886B1 (en) 2003-04-08 2004-04-06 Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol
HRP20100601AA HRP20100601B1 (hr) 2003-04-08 2004-04-06 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol
HR20100600A HRP20100600A2 (hr) 2003-04-08 2004-04-06 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20100601AA HRP20100601B1 (hr) 2003-04-08 2004-04-06 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol
HR20100600A HRP20100600A2 (hr) 2003-04-08 2004-04-06 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol

Country Status (41)

Country Link
US (11) US20060275357A1 (enExample)
EP (5) EP2769713A1 (enExample)
JP (3) JP5495467B2 (enExample)
KR (3) KR20110005320A (enExample)
CN (2) CN101797241B (enExample)
AR (3) AR043987A1 (enExample)
AT (3) AT501681B1 (enExample)
AU (1) AU2004228929B2 (enExample)
BE (2) BE1015972A5 (enExample)
BR (1) BRPI0409250B8 (enExample)
CA (2) CA2521325C (enExample)
CL (2) CL2004000745A1 (enExample)
CY (3) CY1110260T1 (enExample)
DE (4) DE202004021680U1 (enExample)
DK (2) DK2316431T3 (enExample)
EC (1) ECSP056090A (enExample)
ES (3) ES2320767T3 (enExample)
FR (2) FR2854073B1 (enExample)
GB (1) GB2400318B (enExample)
GR (1) GR1005052B (enExample)
HR (3) HRP20050886B1 (enExample)
HU (2) HUE028247T2 (enExample)
IL (3) IL170888A (enExample)
IS (2) IS2682B (enExample)
IT (1) ITMI20040682A1 (enExample)
LU (1) LU91867I2 (enExample)
MA (1) MA27729A1 (enExample)
MX (1) MXPA05010860A (enExample)
MY (1) MY141249A (enExample)
NO (4) NO329332B1 (enExample)
NZ (3) NZ592339A (enExample)
PE (5) PE20150676A1 (enExample)
PL (2) PL1613288T3 (enExample)
PT (1) PT1613288E (enExample)
RU (5) RU2358716C2 (enExample)
SG (1) SG175449A1 (enExample)
SI (2) SI1613288T1 (enExample)
TN (1) TNSN05256A1 (enExample)
TW (1) TWI332847B (enExample)
WO (1) WO2004089341A1 (enExample)
ZA (1) ZA200507394B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5214966B2 (ja) * 2004-07-30 2013-06-19 ノバルティス アーゲー ２−アミノ−１，３−プロパンジオール化合物およびその類似体の製剤
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
CA2820510A1 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
US7687456B2 (en) 2005-11-09 2010-03-30 Proteolix, Inc. Compounds for enzyme inhibition
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2484688B1 (en) 2006-06-19 2016-06-08 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
KR20090057399A (ko) * 2006-09-26 2009-06-05 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
JP4463875B2 (ja) 2007-03-29 2010-05-19 第一三共株式会社 医薬組成物
MX2010003732A (es) 2007-10-04 2010-08-09 Onyx Therapeutics Inc Inhibidores de peptido cetona epoxi de proteasa cristalina y la sintesis de ceto-epoxidos de aminoacido.
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP3733161A1 (en) * 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
BRPI0909625B1 (pt) 2008-03-17 2021-09-08 Actelion Pharmaceuticals Ltd Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
WO2009155475A1 (en) 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
ATE543393T1 (de) * 2008-09-04 2012-02-15 Cargill Inc Erythritol-tablettierung
PE20120059A1 (es) 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
PE20120012A1 (es) 2008-11-11 2012-02-02 Novartis Ag Sales de fingolimod
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
CN102209705A (zh) * 2008-11-11 2011-10-05 诺瓦提斯公司 芬戈莫德盐酸盐的结晶形式
JP5305421B2 (ja) 2008-12-17 2013-10-02 第一三共株式会社 ジアミン誘導体の製造方法
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
ES2542236T3 (es) 2009-03-10 2015-08-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de diamina
WO2010104106A1 (ja) 2009-03-13 2010-09-16 第一三共株式会社 光学活性なジアミン誘導体の製造方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
CN102481296A (zh) * 2009-06-18 2012-05-30 第一三共株式会社 溶解性改善的药用组合物
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CA2793525C (en) 2010-03-19 2014-05-06 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent
ES2560955T3 (es) 2010-03-19 2016-02-23 Daiichi Sankyo Company, Limited Cristal de derivado de diamina y procedimiento de producción del mismo
EA201291095A1 (ru) * 2010-04-22 2013-04-30 Рациофарм Гмбх Способ получения пероральной лекарственной формы, содержащей финголимод
CN103080078B (zh) 2010-07-02 2015-02-11 第一三共株式会社 光学活性二胺衍生物盐的制备方法
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
UA114283C2 (uk) 2011-01-07 2017-05-25 Новартіс Аг Композиції імуносупресантів
PT2665471T (pt) 2011-01-19 2018-03-21 Pathologica Llc Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) * 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
CA2844604C (en) 2011-08-10 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ethanediamide derivatives
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
AU2014205529B2 (en) * 2013-01-08 2018-08-09 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
EP4438037A1 (en) * 2021-01-28 2024-10-02 Priothera SAS Methods of treatment with s1p receptor modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
EP1050301A1 (en) * 1998-01-19 2000-11-08 Yoshitomi Pharmaceutical Industries, Ltd. Medicinal compositions
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
IL121625A (en) 1995-12-28 2001-09-13 Welfide Corp Preparation containing 2 - amino - 2 - (-2 (-4-octylphenyl) ethyl) propane - 1, 3, - dial for local topical use
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
CN1178653C (zh) * 1997-02-27 2004-12-08 三菱制药株式会社 药物组合物
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
BR0112484A (pt) 2000-07-13 2003-09-23 Sankyo Co Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
WO2002076995A2 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003020313A1 (en) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
EP1050301A1 (en) * 1998-01-19 2000-11-08 Yoshitomi Pharmaceutical Industries, Ltd. Medicinal compositions
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Also Published As

Publication number Publication date
TNSN05256A1 (en) 2007-07-10
JP2011006461A (ja) 2011-01-13
EP2769713A1 (en) 2014-08-27
EP2316431B1 (en) 2015-09-30
IL197578A (en) 2015-10-29
HUE028247T2 (en) 2016-12-28
PE20150676A1 (es) 2015-05-17
HK1091114A1 (en) 2007-01-12
ES2228282A1 (es) 2005-04-01
US20140255497A1 (en) 2014-09-11
JP5543298B2 (ja) 2014-07-09
KR20050121712A (ko) 2005-12-27
NO334116B1 (no) 2013-12-16
CN1767819B (zh) 2010-07-28
CA2707750A1 (en) 2004-10-21
ES2320767T3 (es) 2009-05-28
US20200237690A1 (en) 2020-07-30
US20170290787A1 (en) 2017-10-12
AU2004228929A1 (en) 2004-10-21
US20060275357A1 (en) 2006-12-07
PT1613288E (pt) 2009-02-25
ES2556947T3 (es) 2016-01-21
JP5495467B2 (ja) 2014-05-21
AR078781A2 (es) 2011-11-30
RU2358716C2 (ru) 2009-06-20
PE20050396A1 (es) 2005-07-05
LU91867I9 (enExample) 2019-01-03
AT501681A1 (de) 2006-10-15
MY141249A (en) 2010-03-31
US20090203798A1 (en) 2009-08-13
NO20055231D0 (no) 2005-11-07
IS2682B (is) 2010-10-15
SI2316431T1 (sl) 2016-04-29
AT504853A2 (de) 2008-08-15
ZA200507394B (en) 2007-03-28
PE20130200A1 (es) 2013-03-09
SI1613288T1 (sl) 2009-04-30
ECSP056090A (es) 2006-03-01
CN101797241A (zh) 2010-08-11
KR20110005320A (ko) 2011-01-17
JP2013177404A (ja) 2013-09-09
HRP20100601B1 (hr) 2016-12-02
IS8885A (is) 2010-02-25
FR2854073B1 (fr) 2008-03-14
IE20040246A1 (en) 2004-12-15
IL242037A0 (en) 2015-11-30
DK1613288T3 (da) 2009-03-23
JP2004307506A (ja) 2004-11-04
ES2228282B1 (es) 2006-02-16
NO20131287L (no) 2006-01-09
FR11C0036I1 (fr) 2011-10-14
HRP20050886A2 (en) 2006-11-30
SG175449A1 (en) 2011-11-28
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
RU2010147000A (ru) 2012-08-10
BRPI0409250A (pt) 2006-03-28
CA2521325A1 (en) 2004-10-21
GB0407819D0 (en) 2004-05-12
WO2004089341A1 (en) 2004-10-21
US20080311188A1 (en) 2008-12-18
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
GB2400318A (en) 2004-10-13
RU2012148593A (ru) 2014-05-20
NZ592339A (en) 2012-09-28
IL170888A (en) 2010-06-16
DK2316431T3 (en) 2016-01-11
DE202004021680U1 (de) 2010-04-22
CA2521325C (en) 2010-09-14
NO2011016I2 (no) 2012-08-27
MXPA05010860A (es) 2006-05-25
CN1767819A (zh) 2006-05-03
US20110105620A1 (en) 2011-05-05
PL1613288T3 (pl) 2009-07-31
AU2004228929B2 (en) 2008-02-07
GR20040100121A (el) 2004-12-17
BRPI0409250B8 (pt) 2022-01-18
HK1155647A1 (en) 2012-05-25
BRPI0409250B1 (pt) 2017-07-11
EP1613288A1 (en) 2006-01-11
GB2400318B (en) 2005-08-10
ATE414508T1 (de) 2008-12-15
CY1117071T1 (el) 2017-04-05
DE602004017847D1 (de) 2009-01-02
US20130108675A1 (en) 2013-05-02
AR078782A2 (es) 2011-11-30
PE20131352A1 (es) 2013-11-14
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
LU91867I2 (fr) 2011-11-08
MA27729A1 (fr) 2006-01-02
DE102004016947A1 (de) 2004-10-21
CY2011013I2 (el) 2014-04-09
AR043987A1 (es) 2005-08-17
IS8114A (is) 2005-11-01
EP2008650A3 (en) 2011-04-27
AT501681B1 (de) 2012-04-15
IL197578A0 (en) 2011-07-31
NZ542622A (en) 2009-01-31
NZ586280A (en) 2011-12-22
DE122011100047I1 (de) 2011-12-15
RU2475236C2 (ru) 2013-02-20
CL2004000745A1 (es) 2005-02-11
KR101367574B1 (ko) 2014-02-25
CN101797241B (zh) 2013-03-27
HRP20100600A2 (hr) 2011-03-31
HUS1100016I1 (hu) 2016-08-29
NO329332B1 (no) 2010-09-27
NO20100250L (no) 2006-01-09
RU2005134173A (ru) 2006-09-10
US20190175527A1 (en) 2019-06-13
EP2319502A1 (en) 2011-05-11
NO2011016I1 (no) 2011-09-19
EP1613288B1 (en) 2008-11-19
FR11C0036I2 (fr) 2023-12-29
CY2011013I1 (el) 2014-04-09
TW200503784A (en) 2005-02-01
GR1005052B (el) 2005-11-30
RU2010146697A (ru) 2012-05-27
BE2011C030I2 (enExample) 2023-03-07
NO335120B1 (no) 2014-09-22
FR2854073A1 (fr) 2004-10-29
US20220031609A1 (en) 2022-02-03
RU2009105403A (ru) 2010-08-27
KR20120101148A (ko) 2012-09-12
ITMI20040682A1 (it) 2004-07-06
RU2475237C2 (ru) 2013-02-20
US20140011885A1 (en) 2014-01-09
CY1110260T1 (el) 2014-04-09
EP2008650A2 (en) 2008-12-31
PE20090743A1 (es) 2009-07-17
TWI332847B (en) 2010-11-11
US8324283B2 (en) 2012-12-04
HRP20100601A2 (hr) 2011-03-31

Similar Documents

Publication Publication Date Title
HRP20050886B1 (en) Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol
EP4458834A3 (en) Heterocyclic glp-1 agonists
KR970707098A (ko) 브라디키닌 길항제로서 피리도피리미돈, 퀴놀린 및 융합된 N-헤테로사이클(Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists)
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
BRPI0407616A (pt) composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste&#34;
NZ596304A (en) Substituted aminopropionic derivatives as neprilysin inhibitors
AR045551A1 (es) Compuestos fenil o piridil amida como prostaglandina e2 antagonistas
IS8708A (is) Kínasólínafleiður sem æðamyndunarhindranir og milliefni fyrir þær
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
AR039127A1 (es) Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
MXPA05012278A (es) Composiciones para suministrar peptido yy y combatientes pyy.
AR041272A1 (es) Compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) y composicion farmaceutica que los contiene
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
BRPI0513888A (pt) composição medicinal, métodos para a profilaxia ou tratamento de uma doença autoimune, e para preparação da composição medicinal, uso de uma composição medicinal, procedimento de administração, e, agente terapêutico
TW200612936A (en) Indole derivatives
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
SG158925A1 (en) Modulators of chemokine receptor activity, crystalline forms and process
TW200626158A (en) Naphthaline derivatives
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
WO2005117895A8 (en) Compositions comprising meloxicam
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
EA200500672A1 (ru) Содержащие альфузозин композиции с отсроченным высвобождением
TW200503732A (en) Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives and methods of use thereof
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190401

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200330

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210406

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220404

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20230329

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20240406